Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives

Biochemical and Biophysical Research Communications

Volumn 440, Issue 4, 2013, Pages 515-520

  Nakajima, Syo ^a,b   Watashi, Koichi ^a,b   Kamisuki, Shinji ^b   Tsukuda, Senko ^a,c   Takemoto, Kenji ^b   Matsuda, Mami ^a   Suzuki, Ryosuke ^a   Aizaki, Hideki ^a   Sugawara, Fumio ^b   Wakita, Takaji ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c RIKEN   (Japan)

Author keywords

Compound; Entry; HCV; Natural product; Screening; Sulochrin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BENZOIC ACID DERIVATIVE; CYCLOSPORIN A; SULOCHRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; ENDOCYTOSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA REPLICATION; VIRUS ENTRY;

BRYOPHYTA; FUNGI; HEPATITIS C VIRUS;

EID: 84887070091     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.09.100     Document Type: Article

References (33)

1. T.J. Liang, V. Rustgi, E. Galun, and H.E. Blum HCV RNA in patients with chronic hepatitis C treated with interferon-alpha J. Med. Virol. 40 1993 69 75
2. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group N. Engl. J. Med. 339 1998 1485 1492
3. A.W. Tai, and R.T. Chung Treatment failure in hepatitis C: mechanisms of non-response J. Hepatol. 50 2009 412 420
4. V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113
5. B. Bartosch, J. Dubuisson, and F.L. Cosset Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes J. Exp. Med. 197 2003 633 642
6. M. Hsu, J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C.M. Rice, and J.A. McKeating Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles Proc. Natl. Acad. Sci. USA 100 2003 7271 7276
7. T. Wakita, T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H.G. Krausslich, M. Mizokami, R. Bartenschlager, and T.J. Liang Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat. Med. 11 2005 791 796
8. J. Zhong, P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D.R. Burton, S.F. Wieland, S.L. Uprichard, T. Wakita, and F.V. Chisari Robust hepatitis C virus infection in vitro Proc. Natl. Acad. Sci. USA 102 2005 9294 9299
9. B.D. Lindenbach, M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, and C.M. Rice Complete replication of hepatitis C virus in cell culture Science 309 2005 623 626
10. R. Suzuki, K. Saito, T. Kato, M. Shirakura, D. Akazawa, K. Ishii, H. Aizaki, Y. Kanegae, Y. Matsuura, I. Saito, T. Wakita, and T. Suzuki Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection Virology 432 2012 29 38
11. G.M. Cragg, and D.J. Newman Natural products: a continuing source of novel drug leads Biochim. Biophys. Acta 2013 1830 3670 3695
12. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the 30 years from 1981 to 2010 J. Nat. Prod. 75 2012 311 335
13. A.L. Harvey Natural products as a screening resource Curr. Opin. Chem. Biol. 11 2007 480 484
14. S.S. Yang, G.M. Cragg, D.J. Newman, and J.P. Bader Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program J. Nat. Prod. 64 2001 265 277
15. K. Kitazato, Y. Wang, and N. Kobayashi Viral infectious disease and natural products with antiviral activity Drug Discovery Ther. 1 2007 14 22
16. K. Watashi, G. Liang, M. Iwamoto, H. Marusawa, N. Uchida, T. Daito, K. Kitamura, M. Muramatsu, H. Ohashi, T. Kiyohara, R. Suzuki, J. Li, S. Tong, Y. Tanaka, K. Murata, H. Aizaki, T. Wakita, Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase AID, J. Biol. Chem. PMID: 24025329
17. Y. Myobatake, T. Takeuchi, K. Kuramochi, I. Kuriyama, T. Ishido, K. Hirano, F. Sugawara, H. Yoshida, and Y. Mizushina Pinophilins A and B, inhibitors of mammalian A-, B-, and Y-family DNA polymerases and human cancer cell proliferation J. Nat. Prod. 75 2012 135 141
18. A. Murayama, N. Sugiyama, K. Watashi, T. Masaki, R. Suzuki, H. Aizaki, T. Mizuochi, T. Wakita, and T. Kato Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays J. Clin. Microbiol. 50 2012 1943 1949
19. K. Watashi, M. Khan, V.R. Yedavalli, M.L. Yeung, K. Strebel, and K.T. Jeang Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1 J. Virol. 82 2008 9928 9936
20. K. Watashi, M.L. Yeung, M.F. Starost, R.S. Hosmane, and K.T. Jeang Identification of small molecules that suppress microRNA function and reverse tumorigenesis J. Biol. Chem. 285 2010 24707 24716
21. T. Kato, T. Date, M. Miyamoto, M. Sugiyama, Y. Tanaka, E. Orito, T. Ohno, K. Sugihara, I. Hasegawa, K. Fujiwara, K. Ito, A. Ozasa, M. Mizokami, and T. Wakita Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system J. Clin. Microbiol. 43 2005 5679 5684
22. H. Marusawa, M. Hijikata, K. Watashi, T. Chiba, and K. Shimotohno Regulation of Fas-mediated apoptosis by NF-kappa B activity in human hepatocyte derived cell lines Microbiol. Immunol. 45 2001 483 489
23. F. Yasui, M. Sudoh, M. Arai, and M. Kohara Synthetic lipophilic antioxidant BO-653 suppresses HCV replication J. Med. Virol. 85 2013 241 249
24. M.B. Zeisel, I. Fofana, S. Fafi-Kremer, and T.F. Baumert Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies J. Hepatol. 54 2011 566 576
25. E. Blanchard, S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C. Wychowski, and Y. Rouille Hepatitis C virus entry depends on clathrin-mediated endocytosis J. Virol. 80 2006 6964 6972
26. A. Codran, C. Royer, D. Jaeck, M. Bastien-Valle, T.F. Baumert, M.P. Kieny, C.A. Pereira, and J.P. Martin Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis J. Gen. Virol. 87 2006 2583 2593
27. L. Meertens, C. Bertaux, and T. Dragic Hepatitis C virus entry requires a critical postinternalisation step and delivery to early endosomes via clathrin-coated vesicles J. Virol. 80 2006 11571 11578
28. D.K. Cureton, R.H. Massol, S.P. Whelan, and T. Kirchhausen The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis PLoS Pathog. 6 2010 e1001127
29. H.C. Huang, C.C. Chen, W.C. Chang, M.H. Tao, and C. Huang Entry of hepatitis B virus into immortalised human primary hepatocytes by clathrin-dependent endocytosis J. Virol. 86 2012 9443 9453
30. H. Ohashi, M. Ishikawa, J. Ito, A. Ueno, G.J. Gleich, H. Kita, H. Kawai, and H. Fukamachi Sulochrin inhibits eosinophil degranulation J. Antibiotechnol. (Tokyo) 50 1997 972 974
31. H. Ohashi, Y. Motegi, H. Kita, G.J. Gleich, T. Miura, M. Ishikawa, H. Kawai, and H. Fukamachi Sulochrin inhibits eosinophil activation and chemotaxis Inflamm. Res. 47 1998 409 415
32. H.J. Lee, J.H. Lee, B.Y. Hwang, H.S. Kim, and J.J. Lee Fungal metabolites, asterric acid derivatives inhibit vascular endothelial growth factor (VEGF)-induced tube formation of HUVECs J. Antibiotechnol. (Tokyo) 55 2002 552 556
33. R. Nicoletti, E. Manzo, and M.L. Ciavatta Occurence and bioactivities of funicone-related compounds Int. J. Mol. Sci. 10 2009 1430 1444